News

Triumeq is the company’s first dolutegravir-based fixed-dose combination (FDC) which provides HIV patients the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir,

A decision from the European Commission (EC) regarding the approval of ceftolozane/tazobactam is expected during the second half of 2015 The marketing application is based on positive data

The company’s ANDA product is a generic version of UCB’s Neupro, which is designed to treat signs and symptoms of idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs

The company has also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product. The product is

Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware (Case No. 1:14-cv-01088

KanaboSeed was formed to research and develop new breeds of medical Cannabis to meet the requests of physicians and other medical practitioners. Strains developed under the KanaboSeed brand

Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and

The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners and Correlation Ventures also participated in the round. The financing

In the study, Dr. Joshua Atkins, M.D., and colleagues from the Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania in Philadelphia,